Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30209249 | 1.00 | RXFP1 (0.41) | RXFP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL30211551 | 0.86 | RXFP1 (0.41) | RXFP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL260474 | 0.86 | RXFP1 (0.41) | RXFP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4777702 | 0.85 | DGAT1 (0.39) | RXFP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1096910 | 0.81 | ELANE (0.46) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL492395 | 0.81 | POLB (0.37) | DYRK1AALDH1A1POLBMAPT | |
| SCHEMBL24898412 | 0.79 | BCKDK (0.47) | KMT2ACYP2C19DYRK1AKDM4EALDH1A1 | |
| SCHEMBL492471 | 0.79 | MCL1 (0.50) | RXFP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL30211547 | 0.79 | BCKDK (0.47) | KMT2ACYP2C19DYRK1AKDM4EALDH1A1 | |
| SCHEMBL12211158 | 0.79 | MCL1 (0.47) | MEN1KMT2ANPC1RAB9ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113831337-B | GLP-1 receptor agonist, and pharmaceutical composition and use thereof | 广州市恒诺康医药科技有限公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2021259309-A1 | GLP-1 RECEPTOR AGONIST, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2021-12-30 | — | — | WO | disclosed |
| CN-113831337-A | GLP-1 receptor agonist, and pharmaceutical composition and use thereof | 广州市恒诺康医药科技有限公司 | 2021-12-24 | — | — | CN | disclosed |
| US-9328091-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8895566-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| CN-103724343-A | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARM CORP | 2014-04-16 | — | — | CN | disclosed |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | disclosed |
| US-8486937-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2250155-B1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2007-04-05 | — | — | US | disclosed |
| EP-1735306-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050272735-A1 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-12-08 | — | — | US | disclosed |
| US-20050250808-A1 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICAL CORPORATION | 2005-11-10 | — | — | US | disclosed |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-10-20 | — | — | US | disclosed |
| WO-2005092890-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| US-20050176754-A1 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-1543000-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2004-07-08 | — | — | US | disclosed |
| WO-2004029050-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | CHRNA5, CHRNA7, CHRNA3 | RXFP1 962/4885MEN1 4189/4885KMT2A 2648/4885 |
| US-20050272735-A1 | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | CHRNA7, CHRNA1, CHRNA5 | RXFP1 761/4885MEN1 4242/4885KMT2A 2664/4885 |
| US-20050250808-A1 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA2 | RXFP1 828/4885MEN1 3329/4885KMT2A 2762/4885 |
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | RXFP1 4794/4885MEN1 3499/4885KMT2A 4172/4885 |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | RXFP1 1601/4885MEN1 3990/4885KMT2A 3112/4885 |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA2 | RXFP1 1813/4885MEN1 4319/4885KMT2A 3238/4885 |
| US-20050176754-A1 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA1 | RXFP1 552/4885MEN1 3396/4885KMT2A 2391/4885 |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA3 | RXFP1 1563/4885MEN1 3992/4885KMT2A 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.